
RxSight (RXST) Stock Forecast & Price Target
RxSight (RXST) Analyst Ratings
Bulls say
RxSight Inc has demonstrated significant financial strength, evidenced by a gross margin of 71.6%, which increased by 980 basis points year-over-year, surpassing market expectations. The company's revenue from Light Adjustable Lenses (LAL) totaled $28.5 million, marking a robust 60% growth and aligning with consensus estimates, while the revenue from Light Delivery Devices (LDD) remained stable at $10.7 million with a 7% increase. Furthermore, the rising utilization rate of LALs per installed LDD, now at 10.9 from 10.2 in the previous quarter, indicates strong operational momentum that supports the potential for sustained double-digit growth.
Bears say
RxSight Inc. has reported a significant deceleration in the utilization growth of its Light Adjustable Lenses (LAL), which dropped to 9% year-over-year in the fourth quarter of 2024, compared to growth rates between 17% to 22% in the preceding five quarters. The company is facing challenges in the U.S. intraocular lens (IOL) market, where utilization has potentially stagnated, compounded by adverse conditions in the broader cataract surgery market, impacting overall sales performance. Furthermore, the company's financial outlook is concerning as analysts have lowered their earnings per share estimates for 2025 and 2026, citing risks related to market competition, limited adoption of their technology due to additional capital requirements, and the possibility of dilutive financing challenges.
This aggregate rating is based on analysts' research of RxSight and is not a guaranteed prediction by Public.com or investment advice.
RxSight (RXST) Analyst Forecast & Price Prediction
Start investing in RxSight (RXST)
Order type
Buy in
Order amount
Est. shares
0 shares